- Home
- PINE vs CHRS Comparison
PINE vs CHRS Comparison
Compare PINE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | CHRS |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 291.5M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PINE | CHRS |
|---|---|---|
| Price | $18.23 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $20.10 | $5.51 |
| AVG Volume (30 Days) | 206.8K | ★ 1.2M |
| Earning Date | 04-23-2026 | 03-09-2026 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | ★ $60,532,000.00 | N/A |
| Revenue This Year | $18.03 | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | ★ N/A | $1.13 |
| Revenue Growth | ★ 15.90 | N/A |
| 52 Week Low | $13.10 | $0.72 |
| 52 Week High | $20.80 | $2.62 |
Technical Indicators
Market Signals| Indicator | PINE | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 38.63 |
| Support Level | $16.47 | $1.21 |
| Resistance Level | $20.80 | $1.75 |
| Average True Range (ATR) | 0.47 | 0.11 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 0.00 | 1.06 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.